top of page
Search

When Standard Treatment Fails: Dual-Target CAR-T Therapy in China

Key Takeaways

  • Solves "Antigen Escape": Unlike standard therapies, Dual-Target (Tandem) CAR-T attacks two tumor markers simultaneously, significantly reducing the risk of relapse.

  • High Success Rates: Clinical trials in China show up to 100% Overall Response Rates (ORR) for relapsed Multiple Myeloma and high remission rates for B-cell malignancies.

  • Cost-Effective: Treatment costs in China range from $40,000–$180,000 USD, a fraction of the $370,000+ price tag in the US.

  • Concierge Access: MedBridgeNZ connects international patients directly to the top Chinese hospitals pioneering these dual-target treatments.


For patients facing relapsed or refractory blood cancers, the emergence of Chimeric Antigen Receptor (CAR) T-cell therapy has been nothing short of a revolution. However, a significant challenge remains: "antigen escape." This occurs when cancer cells mutate to hide the specific marker that standard CAR-T cells are designed to attack, leading to relapse.

To overcome this, researchers are pioneering Dual-Target CAR-T Therapy in China (also known as Tandem CAR-T). By engineering T-cells to hunt two different tumor markers simultaneously, these next-generation therapies are offering new hope where standard treatments have failed. As a dedicated concierge service for Medical Tourism China, MedBridgeNZ is seeing the country rapidly become the global hub for these advanced, cost-effective life-saving treatments.

Getty Images


When Standard Treatment Fails: Dual-Target CAR-T Therapy in China | MedBridgeNZ Medical Tourism China
When Standard Treatment Fails: Dual-Target CAR-T Therapy in China | MedBridgeNZ Medical Tourism China

The Science Behind Dual-Target CAR-T Therapy China

Standard CAR-T therapy typically targets a single antigen (a protein on the cancer cell surface), such as CD19 for leukemia or BCMA for multiple myeloma. While often effective initially, up to 30-50% of patients may eventually relapse because the tumor stops expressing that single antigen.

Dual-Target CAR-T addresses this by equipping T-cells with two distinct "GPS trackers." For example, instead of just looking for CD19, a dual-target cell might look for CD19 and CD20 simultaneously. If the cancer cell hides one marker, the T-cell can still lock onto the second marker to destroy the tumor. This "bivalent" approach significantly reduces the risk of antigen escape and enhances the durability of the treatment.


Clinical Success Rates of Dual-Target CAR-T in China

China has surpassed the U.S. in the number of active CAR-T clinical trials, producing data that is reshaping global oncology.


1. Multiple Myeloma: The BCMA/CD19 Success

One of the most promising advancements comes from the FasTCAR-T platform (GC012F). In a landmark study involving high-risk newly diagnosed multiple myeloma (NDMM) patients, this dual-target therapy (targeting BCMA and CD19) achieved a 100% Overall Response Rate (ORR).

  • Deep Remission: All 19 evaluable patients achieved stringent complete response (sCR).

  • MRD Negativity: 100% of patients achieved Minimal Residual Disease (MRD) negativity, meaning no cancer cells could be detected using high-sensitivity testing.


2. B-Cell Malignancies: Preventing Relapse

For Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia (ALL), Chinese researchers are utilizing CD19/CD20 and CD19/CD22 dual targets. Clinical trials have shown that these combinations can effectively salvage patients who have relapsed after receiving standard single-target therapies. In one study for relapsed/refractory B-ALL, CD19/CD22 CAR-T cells achieved a 100% MRD-negative complete remission rate in the initial cohort.


3. Solid Tumors: The Next Frontier

While CAR-T has historically struggled with solid tumors, Dual-Target CAR-T Therapy in China is making headway here as well. Innovative trials are targeting Claudin18.2 for gastric and pancreatic cancers. Early results have shown an objective response rate of 48.6% in gastric cancer, significantly higher than global averages for similar single-target trials.


Cost Comparison: Why Choose China for CAR-T?

Beyond clinical innovation, affordability is a primary driver for Medical Tourism China.

In the United States, the cost of commercial CAR-T therapy can range from $370,000 to over $500,000 USD per treatment, excluding hospital stays.

In contrast, CAR-T therapies in China typically range from $40,000 to $180,000 USD.

This price disparity is due to efficient domestic manufacturing, government support for the biotech sector, and a mature clinical trial ecosystem. For international patients, this means access to "best-in-class" technology at a fraction of the cost found in Western healthcare systems.


How MedBridgeNZ Connects You to Treatment

While the medical opportunities are vast, navigating a foreign healthcare system can be complex. This is where MedBridgeNZ serves a vital role.

As a dedicated medical concierge provider, we do not provide medical services ourselves. Instead, we bridge the gap between international patients and China’s top-tier hospitals and research centers. We handle the logistics—from hospital selection and medical visa facilitation to translation and accommodation—ensuring you can focus entirely on your recovery.


--------------------------------------------------------------------------------

This article was written based on clinical data provided by: Dr. Juan Du, MD, PhD Department of Hematology, Myeloma & Lymphoma Center Shanghai Changzheng Hospital

--------------------------------------------------------------------------------


References

1. B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma Source: JAMA Oncology Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11273281/

2. Tandem CAR-T cell therapy: recent advances and current challenges Source: Frontiers in Immunology Link: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1546172/full

3. From molecular design to clinical translation: dual-targeted CAR-T strategies in cancer immunotherapy Source: International Journal of Biological Sciences Link: https://www.ijbs.com/v21p2676.htm

4. CAR-T cell therapy in China: innovations, challenges, and strategic pathways Source: Journal of Hematology & Oncology (via PMC) Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373616/

5. Affordable CAR-T Therapy in China for Cancer Patients Source: PlacidWay Medical Tourism Link: https://www.placidway.com/article/5036/Why-CAR-T-Therapy-in-China-is-a-Game-Changer-for-Cancer-Patients

bottom of page